Therapeutic potential of targeting the oncogenic SHP2 phosphatase

Li Fan Zeng, Ruo Yu Zhang, Zhi Hong Yu, Sijiu Li, Li Wu, Andrea M. Gunawan, Brandon S. Lane, Raghuveer S. Mali, Xingjun Li, Rebecca J. Chan, Reuben Kapur, Clark D. Wells, Zhong Yin Zhang

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


The Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) is an oncogenic phosphatase associated with various kinds of leukemia and solid tumors. Thus, there is substantial interest in developing SHP2 inhibitors as potential anticancer and antileukemia agents. Using a structure-guided and fragment-based library approach, we identified a novel hydroxyindole carboxylic acid-based SHP2 inhibitor 11a-1, with an IC50 value of 200 nM and greater than 5-fold selectivity against 20 mammalian PTPs. Structural and modeling studies reveal that the hydroxyindole carboxylic acid anchors the inhibitor to the SHP2 active site, while interactions of the oxalamide linker and the phenylthiophene tail with residues in the β5- β6 loop contribute to 11a-1's binding potency and selectivity. Evidence suggests that 11a-1 specifically attenuates the SHP2-dependent signaling inside the cell. Moreover, 11a-1 blocks growth factor mediated Erk1/2 and Akt activation and exhibits excellent antiproliferative activity in lung cancer and breast cancer as well as leukemia cell lines.

Original languageEnglish (US)
Pages (from-to)6594-6609
Number of pages16
JournalJournal of Medicinal Chemistry
Issue number15
StatePublished - Aug 14 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint Dive into the research topics of 'Therapeutic potential of targeting the oncogenic SHP2 phosphatase'. Together they form a unique fingerprint.

Cite this